Background {#Sec1}
==========

Chronic kidney disease (CKD) is manifested as the presence of albuminuria, impaired glomerular filtration rate, or both \[[@CR1]\]. It has been found to be associated with an increased risk of cardiovascular morbidity and mortality, bringing heavy social and economic burden subsequently \[[@CR2]--[@CR4]\]. Now, CKD is affecting approximately 13.1% of Americans and 10.8% of Chinese adults \[[@CR5], [@CR6]\]. Although diabetes, hypertension, and family history of CKD, etc., have been established as risk factors for CKD \[[@CR7], [@CR8]\], disclosure of more novel risk factors for CKD or decline in estimated glomerular filtration rate (eGFR), which is a surrogate for development of CKD \[[@CR9]\], may help extensively understand the pathogenesis of CKD and develop new prevention strategies for CKD.

Thyroid hormones, which are crucial for regulation of human body's physiological actions, were found influencing GFR, renal blood flow, tubular secretory and re-absorptive processes as well \[[@CR10]--[@CR12]\]. Previous studies reported that overt and subclinical hypothyroidism were associated with higher levels of serum creatinine, reduced eGFR and increased risk of CKD \[[@CR13]--[@CR16]\]. Hyperthyroidism, however, can also lead to or accelerate the development of CKD \[[@CR17]\]. In fact, most of the evidence was derived from cross-sectional studies \[[@CR18], [@CR19]\]. Prospective studies exploring the effect of thyroid hormones on renal function decline were sparse and got contradictive results \[[@CR20], [@CR21]\]. One study showed that normal-to-high levels of thyroid-stimulating hormone (TSH) and normal-to-low levels of free triiodothyronine (FT3) were associated with an increased risk of incident CKD in euthyroid individuals \[[@CR20]\]. While the other reported non-significant association between thyroid dysfunction and changes in renal function among older adults \[[@CR21]\].

In the present investigation, we aimed to explore prospectively the associations of thyroid hormones with risk of incident CKD and rapid eGFR decline; in addition, we examined the associations with predicted risks for concurrent complications and further outcomes of CKD, among the incident CKD participants.

Methods {#Sec2}
=======

Study population and design {#Sec3}
---------------------------

All participants of the present study were recruited from Songnan Community, Baoshan district, Shanghai, in two stages as reported previously \[[@CR22], [@CR23]\]. In stage 1, 10,185 residents aged 40 years old or above were enrolled to the screening examination in June and July 2008. According to different levels of fasting plasma glucose (FPG), all participants were categorized into three groups: normal glucose regulation, impaired glucose regulation and diabetes. In stage 2, from June to August 2009, 4012 participants were randomly selected from the three groups on a ratio of 1.44 (normal glucose regulation) to 1.2 (impaired glucose regulation) to 1.0 (diabetes) because subjects with lower glucose levels were expected to have a lower participation rate than those with higher glucose levels, for a more comprehensive survey.

Among the 4012 participants, 3455 participants had both blood and urine samples. For the present analysis, participants were excluded sequentially as follows, with a history of thyroid dysfunction (history of overt hyperthyroidism, hypothyroidism or thyroiditis, taking or had previously taken thyroxine or antithyroid drugs, n = 12), currently taking medications which affecting thyroid function (n = 5), with a history of thyroidectomy (n = 2), with inadequate sample for thyroid measurements (n = 42), with missing data on serum creatinine, urinary creatinine and albumin (n = 3), and with eGFR \<60 ml/min/1.73 m^2^ (n = 205) or urinary albumin-to-creatinine ratio (ACR) ≥30 mg/g (n = 309). After exclusion, 2877 participants were eligible. From March to June 2013, all the 2877 participants were invited to have a follow-up study. 26 participants died during the follow-up. Eventually, 2103 participants responded and participated in the follow-up study (details on Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow chart of study participants. *eGFR* estimated glomerular filtration rate, *ACR* albumin--creatinine-ratio

Written informed consent was obtained by each participant and the study protocol was approved by the Institutional Review Board of Rui-Jin Hospital.

Data collection {#Sec4}
---------------

A questionnaire survey and anthropometric measurements were conducted both at the baseline and follow-up visit. Sociodemographics, lifestyle factors and medical history were collected by trained physicians with a standard questionnaire via face-to-face interview. Current drinkers and smokers were defined as those who consumed alcohol at least once a week, and those who smoked a cigarette per day or seven cigarettes per week in the past 6 months, respectively. The information on body weight and height was measured with participants wearing light weight clothing and no shoes. Body mass index (BMI) was calculated as weight in kilograms divided into squared height in meters. Waist circumference was measured at umbilical level in a standing position. After at least 5 min rest, blood pressure was measured three times with 1-min interval using an automated electronic device (OMRON Model HEM-752 FUZZY, Omron Company, Dalian, China), at the non-dominant arm in a seated position. The average of the three readings was used for analysis.

Biochemical measurements {#Sec5}
------------------------

After an at least 10 h overnight fast, the venous sample was collected and a 75-g oral glucose tolerance test (OGTT) was performed for each participant both at the baseline and follow-up visit. Levels of serum triglyceride, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), total cholesterol (TC), and serum creatinine (Cr) were measured by an autoanalyser (ADVIA-1650 Chemistry System, Bayer Corporation, Germany). FPG and OGTT 2-h plasma glucose were measured with using the glucose oxidase method on an autoanalyser (ADVIA-1650 Chemistry System, Bayer Corporation, Germany), and hemoglobin A1c (HbA1c) was determined by high-performance liquid chromatography (BIO-RAD D-10, USA). eGFR was evaluated using the 2009 chronic kidney disease epidemiology collaboration (CKD-EPI) equation \[[@CR24]\] according to the recommendation in the 2012 kidney disease: improving global outcomes (KDIGO) clinical practice guideline for the evaluation and management of CKD \[[@CR1]\]:

\(1\) Females: Cr ≤ 0.7 mg/dl, eGFR = 144 × (Cr/0.7)^−0.329^ × (0.993)^age^; Cr \> 0.7 mg/dl, eGFR = 144 × (Cr/0.7)^−1.209^ × (0.993)^age^. (2) Males: Cr ≤ 0.9 mg/dl, eGFR = 141 × (Cr/0.9)^−0.411^ × (0.993)^age^; Cr \> 0.9mg/dl, eGFR = 141 × (Cr/0.9)^−1.209^ × (0.993)^age^.

A first-voided, early-morning spot urine was collected to measure the urinary albumin and creatinine using rate nephelometry (Beckman Coulter, Fullerton, CA) and alkaline nitroxanthic acid method, respectively. Urinary ACR was calculated as milligrams of urinary albumin excretion per gram of urinary creatinine.

Measurements of thyroid function {#Sec6}
--------------------------------

Levels of serum free thyroxin (FT4), FT3, TSH, thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TGAb) were measured at the baseline by the Clinical Laboratory for Endocrinology, Shanghai Institution of Endocrine and Metabolic Disease, which was certified by College of American Pathologists, and assessed using chemiluminescent microparticle immunoassay method by Architect system (Abbott Laboratories, Abbott Park, IL). The reference ranges of FT4, FT3 and TSH were 9.01--19.04 pmol/l, 2.62--6.49 pmol/l and 0.35--4.94 μIU/ml, respectively, with the corresponding inter-assay coefficients of variations (CV) of 2.6--5.3%, 4.7--8.0%, and 3.1--3.4%. The reference range was \<5.61 IU/ml for TPOAb with an inter-assay CV of 4.3--6.8% and \<4.11 IU/ml for TGAb with an inter-assay CV of 3.2--5.2% \[[@CR23], [@CR25]\].

Outcomes {#Sec7}
--------

In present study, the primary outcome was incident CKD which was defined as the presence of eGFR \<60 ml/min/1.73 m^2^ or urinary ACR ≥30 mg/g at the follow-up visit \[[@CR26]\]. The secondary outcome was rapid eGFR decline which was defined as an annual decline \[(eGFR at follow up---eGFR at baseline)/follow-up period (years)\] in eGFR \>3 ml/min/1.73 m^2^ \[[@CR27]\].

Furthermore, among the participants who developed CKD, we predicted the risks of concurrent complications and further outcomes of CKD by combining eGFR with albuminuria in the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD \[[@CR1]\]. It was classified into four colored risk zones for prognosis: low risk, green; moderately increased risk, yellow; high risk, orange; and very high risk, red.

Statistics analysis {#Sec8}
-------------------

All statistical analyses were performed by using SAS version 9.3 (SAS Institute Inc, Cary, NC, USA). The values of serum TSH, TPOAb, TGAb, triglyceride, FPG and HbA1c, and urinary ACR were normalized by logarithmic transformation because of skewed distributions. Continuous variables were shown as means ± standard deviations (SDs) for those with normal distribution and were shown as medians (interquartile ranges) for those with skewed distribution. All categorical variables were presented as numbers (proportions). Thyroid function measurements were treated as continuous variables with one-unit increase or categorical variables by tertiles: \<13.60, 13.60--14.83 and ≥14.84 pmol/l for serum FT4; \<4.43, 4.43--4.83 and ≥4.84 pmol/l for serum FT3; \<1.151, 1.151--1.860 and ≥1.861 μIU/ml for serum TSH.

Comparisons of baseline characteristics between non-CKD and incident CKD individuals were performed by using *t* test for continuous variables and Chi-square test for categorical variables. *P* values for trend for percentages of incident CKD and rapid eGFR decline were tested by using Cochran--Mantel--Haenszel (CMH) method among tertiles of serum FT4.

Multivariable logistic regression analysis was used to evaluate the associations of serum FT4, as well as serum FT3 and TSH, with the development of CKD and rapid eGFR decline. In model 1, age, sex and BMI at baseline were adjusted; in model 2, triglyceride, HDL-c, urinary ACR (for incident CKD only) and eGFR, current smoking and drinking, diabetes and hypertension status, and usage of antidiabetic or antihypertensive drugs at baseline were further adjusted based on model 1; in model 3, serum TPOAb and TGAb levels at baseline were further adjusted based on model 2. Additionally, we used the multinomial logit regression analysis to evaluate the associations of baseline serum FT4 levels with the predicted risks for future outcomes of CKD, among incident CKD individuals.

Significance tests were two-tailed and a *P* value less than 0.05 was considered to be statistically significant.

Results {#Sec9}
=======

Characteristics of the participants at baseline {#Sec10}
-----------------------------------------------

A total of 2103 participants free of CKD at baseline were included in current analyses. The mean age was 59.3 years old and 39.3% were males. During the 4-year follow-up period, 198 (9.4%) participants developed CKD and 165 (7.8%) experienced rapid eGFR decline. Table [1](#Tab1){ref-type="table"} shows baseline characteristics of the participants according to incident CKD status. Participants who developed CKD were older, had higher BMI, waist circumference, blood pressure, serum triglyceride, FPG, HbA1c and urinary ACR, and lower level of eGFR (all *P* values \<0.05). 26.3% of those who developed CKD at follow-up were taking antidiabetic drugs and 31.8% were using antihypertensive drugs, significantly higher than that of non-CKD participants (all *P* values \<0.05). In particular, levels of serum FT4, but not FT3 and TSH, were higher among the incident CKD participants than non-CKD ones (*P* \< 0.0001). No significant differences were observed in levels of HDL-c, LDL-c, TC, TPOAb, TGAb, sex distribution, or status of current smoking and drinking at baseline between incident CKD and non-CKD participants.Table 1Baseline characteristics of the participants according to incident CKD statusCharacteristicsNon-CKDIncident CKD*P* valuen, %1905 (90.6)198 (9.4)--Age (years)58.9 ± 8.963.1 ± 10.1\<0.0001Male (n, %)753 (39.5)73 (36.9)0.47BMI (kg/m^2^)24.7 ± 3.425.5 ± 3.80.0006Waist circumference (cm)86.3 ± 9.489.5 ± 9.7\<0.0001Current drinker (n, %)344 (18.1)40 (20.2)0.58Current smoker (n, %)382 (20.1)39 (19.7)0.81SBP (mmHg)134 ± 24144 ± 27\<0.0001DBP (mmHg)78 ± 1081 ± 100.001Triglyceride (mmol/l)1.40 (0.96--2.02)1.48 (1.01--2.41)0.02LDL-C (mmol/l)2.40 ± 0.682.35 ± 0.680.30HDL-C (mmol/l)1.37 ± 0.301.34 ± 0.310.31Total cholesterol (mmol/l)5.15 ± 0.965.11 ± 1.050.64FPG (mmol/l)5.1 (4.7--5.8)5.6 (5.0--7.0)\<0.0001HbA1c (%)6.1 (5.7--6.5)6.4 (5.9--7.6)\<0.0001TSH (μIU/ml)1.44 (1.03--2.14)1.44 (1.01--2.07)0.35FT3 (pmol/l)4.65 ± 0.554.72 ± 1.110.16FT4 (pmol/l)14.27 ± 1.8014.85 ± 2.36\<0.0001TPOAb (IU/ml)0.30 (0.17--0.73)0.32 (0.18--0.71)0.55TGAb (IU/ml)1.06 (0.71--2.44)0.93 (0.71--1.91)0.09eGFR (ml/min/1.73 m^2^)92.4 ± 12.288.9 ± 14.40.0001Urinary ACR (mg/g)4.67 (2.39--8.71)9.57 (4.41--16.87)\<0.0001Use of antidiabetic drugs (n, %)208 (10.9)52 (26.3)\<0.0001Use of antihypertensive drugs (n, %)426 (22.4)63 (31.8)0.003*P* values are calculated by *t* test for continuous variables and Chi-square test for categorical variablesData are means ± standard deviations or medians (interquartile ranges) for continuous variables, and numbers (proportions) for categorical variables*ACR* albumin-to-creatinine ratio, *BMI* body mass index, *DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate, *FT3* free triiodothyronine, *FT4* free thyroxine, *FPG* fasting plasma glucose, *HDL-c* high-density lipoprotein cholesterol, *HbA1c* hemoglobin A1c, *LDL-c* low-density lipoprotein cholesterol, *SBP* systolic blood pressure, *TSH* thyroid-stimulating hormone, *TPOAb* thyroid peroxidase antibody, *TGAb* thyroglobulin antibody

Association of thyroid hormones with incident CKD {#Sec11}
-------------------------------------------------

The incidence of CKD gradually increased according to serum FT4 tertiles: 6.7, 8.6 and 12.9% for tertile 1, tertile 2 and tertile 3, respectively. As compared to tertile 1, tertile 3 of FT4 levels was associated with 88% increased risk of developing CKD (95% confidence interval \[CI\] 1.27--2.77; *P* for trend = 0.001), after adjustment for the confounding factors (Model 3). The continuous variable analysis showed similar results. Each 1-pmol/l of FT4 was associated with 12% (95% CI 1.05--1.20) increased risk of incident CKD. We did not found a significant association between serum FT3 or TSH and incident CKD (Table [2](#Tab2){ref-type="table"}).Table 2Association of thyroid hormone levels with incident CKDCase/number (%)Model 1Model 2Model 3Serum FT4 Tertile 147/699 (6.7)1.001.001.00 Tertile 260/701 (8.6)1.28 (0.86--1.91)1.26 (0.83--1.91)1.24 (0.82--1.88) Tertile 391/703 (12.9)1.97 (1.36--2.86)1.91 (1.30--2.81)1.88 (1.27--2.77) *P* for trend\<0.00010.00030.00080.001 Each 1-pmol/l increase in FT4198/2103 (9.4)1.13 (1.05--1.21)1.12 (1.04--1.20)1.12 (1.05--1.20)Serum FT3 Tertile 165/687 (9.5)1.001.001.00 Tertile 268/712 (9.6)1.07 (0.74--1.53)1.11 (0.76--1.62)1.12 (0.76--1.63) Tertile 365/704 (9.2)1.09 (0.75--1.59)1.06 (0.72--1.57)1.04 (0.70--1.54) *P* for trend0.880.640.760.86 Each 1-pmol/l increase in FT3198/2103 (9.4)1.23 (1.01--1.49)1.21 (0.99--1.49)1.20 (0.98--1.47)Serum TSH Tertile 164/700 (9.1)1.001.001.00 Tertile 274/700 (10.6)1.13 (0.79--1.61)1.31 (0.90--1.90)1.34 (0.92--1.94) Tertile 360/703 (8.5)0.86 (0.59--1.26)0.99 (0.66--1.47)1.04 (0.69--1.56) *P* for trend0.700.450.990.80 Each 1-μIU/ml increase in TSH198/2103 (9.4)0.99 (0.91--1.07)0.99 (0.92--1.07)1.00 (0.94--1.07)Model 1: adjusted for age, sex, BMI at baselineModel 2: further adjusted for triglyceride, HDL-c, diabetes and hypertension status, current smoking and drinking status, use of antihypertensive drugs, use of antidiabetic drugs, urinary ACR, eGFR at baselineModel 3: further adjusted for TPOAb, TGAb at baseline*P* for trend values for percentages of incident CKD are calculated by using Cochran--Mantel--Haenszel (CMH) methodData are odds ratios (95% confidence intervals)*ACR* albumin-to-creatinine ratio, *BMI* body mass index, *CKD* chronic kidney disease, *eGFR* estimated glomerular filtration rate, *FT3* free triiodothyronine, *FT4* free thyroxine, *HDL-c* high-density lipoprotein cholesterol, *TSH* thyroid-stimulating hormone, *TPOAb* thyroid peroxidase antibody, *TGAb* thyroglobulin antibody

Association of thyroid hormones with rapid eGFR decline during follow-up {#Sec12}
------------------------------------------------------------------------

During follow-up, the eGFR levels of non-CKD individuals significantly increased, while those of incident CKD participants were decreased (all *P* values \<0.05). In follow-up study, eGFR of non-CKD and incident CKD individuals were 93.0 ± 10.6 and 84.1 ± 18.1 ml/min/1.73 m^2^, respectively. With the increment of serum FT4 tertiles, the percentages of rapid eGFR decline gradually increased (*P* for trend = 0.0004). Multivariable logistic regressions showed that the odds ratio (OR) for rapid eGFR decline in the highest FT4 tertile versus the lowest tertile was 1.64 (95% CI 1.07--2.50), after adjustment for various confounders. Each 1-pmol/l increase of serum FT4 was associated with 10% increased risk of rapid eGFR decline. We did not found a significant association between serum FT3 or TSH and risk of rapid eGFR decline (Table [3](#Tab3){ref-type="table"}).Table 3Association of thyroid hormones with rapid eGFR decline during follow-upCase/number (%)Model 1Model 2Model 3Serum FT4 Tertile 140/699 (5.7)1.001.001.00 Tertile 256/701 (8.0)1.40 (0.92--2.14)1.38 (0.89--2.12)1.40 (0.91--2.16) Tertile 369/703 (9.8)1.72 (1.15--2.59)1.61 (1.06--2.45)1.64 (1.07--2.50) *P* for trend0.00040.0090.030.02 Each 1-pmol/l increase in FT4165/2103 (7.9)1.12 (1.05--1.21)1.10 (1.02--1.18)1.10 (1.03--1.18)Serum FT3 Tertile 155/687 (8.0)1.001.001.00 Tertile 269/712 (9.7)1.29 (0.89--1.87)1.35 (0.91--1.99)1.36 (0.92--2.00) Tertile 341/704 (5.8)0.79 (0.51--1.21)0.84 (0.54--1.30)0.83 (0.53--1.30) *P* for trend0.0250.330.500.49 Each 1-pmol/l increase in FT3165/2103 (7.9)1.17 (0.95--1.44)1.14 (0.93--1.40)1.13 (0.92--1.39)Serum TSH Tertile 163/700 (9.0)1.001.001.00 Tertile 253/700 (7.6)0.77 (0.53--1.14)0.85 (0.57--1.26)0.85 (0.57--1.26) Tertile 349/703 (7.0)0.67 (0.44--0.99)0.75 (0.50--1.15)0.74 (0.49--1.14) *P* for trend0.350.0460.180.17 Each 1-μIU/ml increase in TSH165/2103 (7.9)0.97 (0.88--1.08)1.00 (0.92--1.08)1.00 (0.92--1.08)Model 1: adjusted for age, sex, BMI at baselineModel 2: further adjusted for triglyceride, HDL-c, diabetes and hypertension status, current smoking and drinking status, use of antihypertensive drugs, use of antidiabetic drugs, eGFR at baselineModel 3: Further adjusted for TPOAb, TGAb at baseline*P* for trend values for percentages of rapid eGFR decline are calculated by using Cochran--Mantel--Haenszel (CMH) methodData are odds ratios (95% confidence intervals)*BMI* body mass index, *eGFR* estimated glomerular filtration rate, *FT3* free triiodothyronine, *FT4* free thyroxine, *HDL-c* high-density lipoprotein cholesterol, *TSH* thyroid-stimulating hormone, *TPOAb* thyroid peroxidase antibody, *TGAb* thyroglobulin antibody

Association of baseline serum FT4 levels with the predicted risks for future outcomes of CKD {#Sec13}
--------------------------------------------------------------------------------------------

According to the recommendations in the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD \[[@CR1]\], among the 198 participants who developed CKD during follow-up, 177 participants were at moderately increased risk of concurrent complications and further outcomes of CKD, 17 and 4 were at high risk and very high risk, respectively.

Table [4](#Tab4){ref-type="table"} shows associations of baseline serum FT4 levels with the predicted risks for future outcomes of CKD, among incident CKD individuals. After adjusting for a wide range of covariates, each 1-pmol/l increase and each 1-tertile increase of FT4 associated 11% and 30% increased risk for moderately increased risk of concurrent complications and further outcomes of CKD, respectively; and 22% and 161% increased risk for the combined high and very high increased risk of concurrent complications and further outcomes among incident CKD individuals, respectively.Table 4Association of baseline FT4 with predicted risks for future outcomes of incident CKDPredicted risks for future outcomes of incident CKDModerately increased riskCombined high and very high increased riskCase/number (%)177/2103 (8.4)21/2103 (1.0)Each 1-pmol/l increase in FT4 Model 11.12 (1.04--1.21)1.18 (1.05--1.34) Model 21.11 (1.03--1.19)1.22 (1.06--1.41)Each 1-tertile increase in FT4 Model 11.33 (1.09--1.61)2.73 (1.41--5.27) Model 21.30 (1.06--1.59)2.61 (1.32--5.16)Model 1: adjusted for age, sex, BMI at baselineModel 2: further adjusted for triglyceride, HDL-c, diabetes and hypertension status, current smoking and drinking status, use of antihypertensive drugs, use of antidiabetic drugs, urinary ACR, eGFR, TPOAb and TGAb at baselineData are odds ratios (95% confidence intervals), calculated by using multinomial logit regression analysis, referenced to low risk of prognosis of incident CKD*ACR* albumin-to-creatinine ratio, *BMI* body mass index, *CKD* chronic kidney disease, *eGFR* estimated glomerular filtration rate, *FT4* free thyroxine, *HDL-c* high-density lipoprotein cholesterol, *TPOAb* thyroid peroxidase antibody, *TGAb* thyroglobulin antibody

Discussion {#Sec14}
==========

In this community-based prospective investigation, we found that high levels of serum FT4 significantly associated with renal function decline in middle-aged and elderly Chinese. Major findings in our study were: (1) elevated levels of serum FT4 at baseline associated with increased risk of incident CKD and rapid eGFR decline; (2) serum FT4 positively associated with the increased risk for concurrent complications and further outcomes of CKD; (3) no significant associations of serum FT3, TSH with incident CKD or rapid eGFR decline were found in the present analysis.

In our study, we reported significant associations of FT4 with both incident CKD and rapid eGFR decline in a large general Chinese population, suggesting that when a higher FT4 level was found in clinical practice, a screening for kidney disease is warranted beyond hyperthyroidism treatments and the thyroid function monitoring. Our results were consistent with several previous findings. A prospective study focusing on thyroid function status and renal function in older persons found that overt hypothyroidism provided a protective effect on changes in renal function over time, whereas hyperthyroidism conveyed a harmful effect \[[@CR21]\]. In addition, other perspective studies also demonstrated that overt and subclinical hypothyroidism in older age (\>85 years old) might even have a protective effect, particularly on span of life \[[@CR28], [@CR29]\]. However, our findings were conflicted with the results from the Kangbuk Samsung Health Study (KSHS), which was performed among 104,633 Korean participants with an average age of 38.0 years old and normal thyroid function at baseline. It reported that high-normal levels of TSH and low-normal FT3 levels below 3 pg/ml, but not FT4 levels, were associated with increased risk of incident CKD, defined as eGFR \<60 mL/min/1.73 m^2^ \[[@CR20]\]. The disparate definitions of CKD might be a possible attributor for this discrepancy. In our study, we defined CKD not only on basis of eGFR but also on the presence of albuminuria. Albuminuria would be induced by high thyroid function and then could deteriorate renal function gradually \[[@CR17], [@CR30]\]. In addition, it might be due to the relatively older participants in our study than those in KSHS. With the increasing age, renal function declined \[[@CR31]\] and thyroid function changed including increase of serum TSH and FT4, and decrease of total triiodothyronine \[[@CR32]\].

In our study, we found that high levels of FT4, but not low levels of TSH, associated with incident CKD and rapid eGFR decline. Analogously, Ahmed MM reported that high levels of FT4, but not low levels of TSH, significantly associated with increasing severity of renal failure in patients with chronic renal failure and averagely aged 61 years old \[[@CR33]\]. It might be partially due to the reduced sensitivity of pituitary with the increasing age; and then high FT4 levels could not generate negative feedback to TSH and suppress secretion of TSH \[[@CR32], [@CR34]\]. As shown in our study, serum FT4 was positively associated with age (*β* = 0.012, *P* = 0.0086), but TSH was not (*β* = −0.0021, *P* = 0.27).

However, the mechanisms of the positive associations of serum FT4 levels with incident CKD and rapid eGFR decline remain unclear. It might be due to the fact that high thyroid hormone levels increased the permeability of the glomerular barrier, and subsequently led to proteinuria \[[@CR35]\]. Several studies have reported that overt proteinuria was observed in hyperthyroid rats, as well as in Graves' disease patients \[[@CR36]\]. It may also be possible that the presence of albuminuria could promote renal function deterioration. Previous studies found that the elevated ACR, even within normal range, was associated with a faster decline in eGFR \[[@CR37], [@CR38]\].

The major strength of our study is the prospective nature. We also carefully performed adjustments for the potential confounders, including the autoimmune thyroid antibodies. Besides, the CKD was defined based on either eGFR \<60 ml/min/1.73 m^2^ or presence of albuminuria recommended by the 2012 KDIGO clinical practice guideline. The rationales arise from the evidence that decrease eGFR or albuminuria were consistently associated with increased risk of death, end stage renal disease or cardiovascular mortality \[[@CR39]\]. However, several limitations should be acknowledged. Firstly, the GFR was estimated by the 2009 CKD-EPI equation, rather than the gold standard of GFR measurement, a technetium 99m diethylene-triaminepentaacetic acid (^99m^Tc-DTPA) renal dynamic imaging method. However, the accuracy of CKD-EPI equation to estimate GFR has already been confirmed and validated in many previous studies \[[@CR40], [@CR41]\]. Secondly, urinary albumin and creatinine were measured using a single spot urine sample. However, it was more practicable in large epidemiological studies \[[@CR6]\], and was highly agree with the 24-h urinary albumin excretion \[[@CR42], [@CR43]\]. Thirdly, there were only two measurements of eGFR rather than repeated measurements of eGFR during follow-up. Fourthly, the current study was conducted in middle-aged and elderly Chinese adults. Hence, more cautions are needed to generalize the findings to other age and ethnic groups.

Conclusions {#Sec15}
===========

In conclusion, the present study indicated that a high level of serum FT4, rather than serum TSH and FT3, was associated with increased risk of incident CKD, rapid eGFR decline and increased risks of concurrent complications and further outcomes of CKD. Further studies aimed to validate our findings in other age and other ethnic groups, to examine the association of developing hyperthyroidism with incident CKD, and to explore related mechanisms are warranted in the future.
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